

22 August 2023

Market Announcements Office  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

**Bod Science Limited (ASX: BOD)**

**Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)**

Bod Science Limited (ASX:BOD) ACN 601 225 441 (the **Company** or **Bod**) has today issued 2,500,000 fully paid ordinary shares in the Company (**Shares**) to professional and sophisticated investors under a share placement which was announced to ASX on 3 August 2023 (**Placement**).

A total of 1,875,000 Shares remain to be issued to Chair, David Baker, under the Placement (subject to shareholder approval).

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**) that:

1. the Company issued 2,500,000 Shares without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice the Company has complied with:
  - a. the provisions of Chapter 2M of the Act as they apply to Bod; and
  - b. sections 674 and 674A of the Act;
3. there is no information that is 'excluded information' (within the meaning of section 708A(7) and section 708A(8) of the Act).

ENDS

**This announcement has been approved by the Board of Bod Science Limited.**

**About Bod Science:**

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
Info@bodscience.com  
+61 2 9199 5018

Amalie Schreurs  
White Noise Communications  
amalie@whitenoisecomms.com  
+61 431 636 033